AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$CMPS

Compass Pathways could secure US approval for depression drug by early 2027, Jefferies says

Jefferies predicts Compass Pathways (CMPS) may gain FDA approval for its psilocybin-based depression drug COMP360 by early 2027, with a potential US launch and $31M revenue. The forecast is based on completed NDA submission, positive clinical data, and expedited review. The drug targets treatment-resistant depression, with potential benefits over JNJ's Spravato.

Original reporting
finance.yahoo.com
Published Nov 9, 2026, 7:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 7:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Compass Pathways could secure US approval for depression drug by early 2027, Jefferies says — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$CMPSBullishHigh
01

Why it matters

The early approval forecast could materially affect CMPS valuation and the broader psychedelic‑therapy market.

02

Market read

First disclosure of an expedited FDA review timeline for a psychedelic drug, a catalyst for CMPS and sector peers.

03

What to watch

Pricing assumptions and reimbursement landscape could limit commercial upside.

Relevance 8/10Novelty 8/10Timing: pre-market ahead of potential early 2027 approval

Background

Compass Pathways is developing COMP360, an oral psilocybin treatment for treatment‑resistant depression, with Phase III data already positive.

Company-level read

Ticker impact

$CMPSBullishHigh confidence
Context

Jefferies forecasts Compass Pathways could receive FDA approval for its depression drug COMP360 as early as Dec 2026/Jan 2027, a new regulatory timeline.

Expected impact

likely upside as investors price in early approval and commercial launch.

Evidence & confidence

First report of an expedited FDA review and early launch timeline; market has not priced this specific catalyst yet.

Market effects

Sector

Could boost the biotech sector focused on psychedelic therapies and encourage similar pipelines.

Regional

U.S. biotech investors may see increased interest; limited direct impact elsewhere.

Global

Sets a precedent for regulatory pathways of psychedelic drugs worldwide.

Counterpoint

What could challenge this read

Regulatory risk remains high; FDA may still delay or reject despite Jefferies' optimism.

Key entities

  • company
    Compass Pathways

    Biotech developing psilocybin‑based depression therapy.

  • analyst
    Jefferies

    Broker providing the approval timeline forecast.

Read at source← All news

StoryCompass Pathways completes FDA application for COMP360

Also covered by

3 outlets

Related articles

$CMPSHighAI 9/10

Compass Pathways stock gains on FDA filing for depression drug

Compass Pathways (CMPS) shares rose 4.5% after submitting a New Drug Application to the FDA for its psilocybin-based depression treatment, COMP360. The submission is backed by positive Phase 3 trial data. The company expects a potential launch in early 2027, pending FDA approval. Jefferies reiterated a Buy rating and $18.00 price target, citing high confidence in FDA approval.

investing.com
$CMPSMedAI 8/10

Compass Pathfinder Limited: Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression

Compass Pathways (CMPS) submitted a New Drug Application (NDA) to the U.S. FDA for COMP360 psilocybin to treat treatment-resistant depression (TRD). The submission is backed by data from Phase 3 trials and a Phase 2b study involving over 1,000 participants. The company aims for a potential launch in the first half of 2027, pending FDA approval.

finanznachrichten.de
$CMPSHigh

Oppenheimer reiterates Compass Pathways stock rating on NDA filing

Oppenheimer maintained an Outperform rating and $20 price target for Compass Pathways (CMPS) after its Q3 update. The company expects to file an NDA for COMP360 within two weeks, aiming for a 2027 launch. CMPS reported $56M in operating expenses, $444M in cash, and a Q3 loss of $0.31 per share, beating estimates. Analysts from TD Cowen, BTIG, and Stifel also reiterated Buy ratings with higher price targets, citing strong execution and trial results.

investing.com
$CMPSMed

Compass Pathways (CMPS) Q3 2026 Earnings Call Transcript

Compass Pathways (CMPS) expects to complete its NDA submission for COMP360 in two weeks, with a potential rapid approval due to a National Priority Voucher. The company has $444M in cash and is preparing for a 2027 launch, targeting treatment-resistant depression (TRD) and exploring PTSD as a label expansion. Management expressed confidence in COMP360's efficacy and market potential, citing positive clinical data and strong commercial team.

finance.yahoo.com